<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1 INDICATIONS AND USAGE<BR>               <BR>               <BR>                  <BR>                     <BR>                        BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directed radiotherapeutic antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. (1.1)<BR>                        <BR>                        Determination of the effectiveness of the BEXXAR therapeutic regimen is based on overall response rates in patients whose disease is refractory to chemotherapy and rituximab. The effects of the BEXXAR therapeutic regimen on survival are not known. (1.1)<BR>                        <BR>                        <BR>                           Important Limitation of Use<BR>                        <BR>                        <BR>                           <BR>                              •BEXXAR therapeutic regimen is only indicated for a single course of treatment and is not indicated for a first-line treatment. (1.2)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1 Relapsed or Refractory CD20-Positive, Non-Hodgkin’s Lymphoma<BR>                     <BR>                        <BR>                           The BEXXAR® therapeutic regimen (tositumomab and iodine I 131 tositumomab) is indicated for the treatment of patients with CD20-positive relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. <BR>                        <BR>                        <BR>                           Determination of the effectiveness of the BEXXAR therapeutic regimen is based on overall response rates in patients whose disease is refractory to chemotherapy and rituximab. The effects of the BEXXAR therapeutic regimen on survival are not known.   <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.2 Important Limitations of Use<BR>                     <BR>                        <BR>                           <BR>                              •The BEXXAR therapeutic regimen is only indicated for a single course of treatment. <BR>                           <BR>                              •The safety and efficacy of additional courses of the BEXXAR therapeutic regimen have not been established.<BR>                           <BR>                              •The BEXXAR therapeutic regimen is not indicated for first-line treatment of patients with CD20-positive non-Hodgkin's lymphoma.<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>